Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477130 | 0.84 | PDE7A (0.49) | APLNRALDH1A1PDE7AMEN1KMT2A | |
| SCHEMBL5470187 | 0.80 | APLNR (0.47) | APLNRALDH1A1L3MBTL1PDE7AMEN1 | |
| SCHEMBL5477516 | 0.78 | ALDH1A1 (0.50) | APLNRALDH1A1L3MBTL1PDE7AMEN1 | |
| SCHEMBL5484755 | 0.74 | ALDH1A1 (0.56) | ALDH1A1PDE7AMEN1LMNAKMT2A | |
| SCHEMBL5470190 | 0.73 | APLNR (0.47) | APLNRALDH1A1L3MBTL1PDE7AMEN1 | |
| SCHEMBL5484751 | 0.72 | HSD11B1 (0.39) | ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL5484762 | 0.70 | ALDH1A1 (0.62) | ALDH1A1PDE7AMEN1KMT2AMAPT | |
| SCHEMBL21589376 | 0.70 | PIK3C2A (0.61) | ALDH1A1LMNATP53MAPTPOLB | |
| SCHEMBL5446865 | 0.68 | MAOB (0.48) | L3MBTL1PDE7AMEN1KMT2AMAPT | |
| SCHEMBL1129585 | 0.68 | PDE7A (0.73) | APLNRALDH1A1L3MBTL1PDE7ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | APLNR 1635/4885ALDH1A1 825/4885L3MBTL1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.